BR112017006969A2 - peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno - Google Patents
peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígenoInfo
- Publication number
- BR112017006969A2 BR112017006969A2 BR112017006969A BR112017006969A BR112017006969A2 BR 112017006969 A2 BR112017006969 A2 BR 112017006969A2 BR 112017006969 A BR112017006969 A BR 112017006969A BR 112017006969 A BR112017006969 A BR 112017006969A BR 112017006969 A2 BR112017006969 A2 BR 112017006969A2
- Authority
- BR
- Brazil
- Prior art keywords
- hsp70
- treating
- pharmaceutical composition
- production method
- same
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 title 1
- 101150031823 HSP70 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 210000000612 antigen-presenting cell Anatomy 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 101150052825 dnaK gene Proteins 0.000 title 1
- 210000002443 helper t lymphocyte Anatomy 0.000 title 1
- 230000036039 immunity Effects 0.000 title 1
- 239000000411 inducer Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001176—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464476—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/53—Liver
Abstract
a presente invenção refere-se a um peptídeo contendo 8 ou mais resíduos de aminoácidos consecutivos em uma sequência de aminoácidos de qualquer uma das seq id nos: 1 a 15 e consistindo em 11 ou menos resíduos de aminoácidos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014206730 | 2014-10-07 | ||
PCT/JP2015/078504 WO2016056596A1 (ja) | 2014-10-07 | 2015-10-07 | Hsp70由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017006969A2 true BR112017006969A2 (pt) | 2017-12-19 |
Family
ID=55653202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017006969A BR112017006969A2 (pt) | 2014-10-07 | 2015-10-07 | peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno |
Country Status (12)
Country | Link |
---|---|
US (3) | US10537626B2 (pt) |
EP (2) | EP3205661B1 (pt) |
JP (1) | JP6423889B2 (pt) |
CN (1) | CN107001418A (pt) |
AU (2) | AU2015329070B2 (pt) |
BR (1) | BR112017006969A2 (pt) |
CA (2) | CA3116265A1 (pt) |
DK (1) | DK3205661T3 (pt) |
ES (1) | ES2882827T3 (pt) |
RU (1) | RU2684911C2 (pt) |
TW (1) | TWI687434B (pt) |
WO (1) | WO2016056596A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016056596A1 (ja) | 2014-10-07 | 2016-04-14 | 日本電気株式会社 | Hsp70由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
US10526388B2 (en) | 2015-03-09 | 2020-01-07 | Cytlimic Inc. | Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells |
EP3281641B1 (en) | 2015-04-07 | 2020-12-16 | Cytlimic Inc. | Adjuvant for cancer vaccines |
US11291718B2 (en) | 2016-10-11 | 2022-04-05 | Cytlimic Inc. | Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein |
WO2023163094A1 (ja) * | 2022-02-25 | 2023-08-31 | 日本電気株式会社 | 成人t細胞白血病の治療又は予防のための医薬組成物 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196523A (en) * | 1985-01-01 | 1993-03-23 | The University Of Southern California | Control of gene expression by glucose, calcium and temperature |
JPH08151396A (ja) | 1994-11-28 | 1996-06-11 | Teijin Ltd | Hla結合性オリゴペプチド及びそれを含有する免疫調節剤 |
EP0893507A1 (en) | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
EP1319023B8 (en) * | 2000-09-13 | 2009-07-15 | multimmune GmbH | An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof |
JP2005523236A (ja) * | 2001-07-31 | 2005-08-04 | ペプジェン コーポレイション | 免疫応答調節組成物および方法 |
JP4406607B2 (ja) | 2002-08-26 | 2010-02-03 | オンコセラピー・サイエンス株式会社 | ペプチド及びこれを含む医薬 |
EP2572715A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
FR2863890B1 (fr) | 2003-12-19 | 2006-03-24 | Aventis Pasteur | Composition immunostimulante |
WO2006004182A1 (ja) | 2004-07-07 | 2006-01-12 | Nec Corporation | 配列予測システム |
EP1881844A2 (en) | 2005-05-19 | 2008-01-30 | GlaxoSmithKline Biologicals S.A. | Vaccine composition comprising b-subunit of e.coli heat labile toxin and an antigen and an adjuvant |
AU2006277295B2 (en) | 2005-08-09 | 2011-08-11 | Oncotherapy Science, Inc. | Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same |
US20100015101A1 (en) | 2006-03-28 | 2010-01-21 | Noriyuki Sato | Novel tumor antigen peptides |
RU2333767C2 (ru) | 2006-03-31 | 2008-09-20 | Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") | Вакцинные композиции, способы их применения для профилактики и лечения меланомы и генетические конструкции для получения действующих компонентов композиции |
CN102850434B (zh) * | 2006-10-17 | 2016-04-13 | 肿瘤疗法科学股份有限公司 | 用于表达mphosph1或depdc1多肽的癌症的肽疫苗 |
WO2008106491A2 (en) * | 2007-02-27 | 2008-09-04 | University Of Utah Research Foundation | Peptides that interact with topoisomerase i and methods thereof |
CN101801402B (zh) * | 2007-07-06 | 2013-08-28 | 乌得勒支大学控股有限公司 | 炎性疾病和自身免疫疾病的治疗和预防 |
WO2009036349A1 (en) | 2007-09-12 | 2009-03-19 | Anaphore, Inc. | Hsp70-based treatment for autoimmune diseases |
KR100900837B1 (ko) | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물 |
US20120225090A1 (en) * | 2009-08-03 | 2012-09-06 | The Johns Hopkins University | Methods for enhancing antigen-specific immune responses |
MY163110A (en) | 2009-10-06 | 2017-08-15 | Panacela Labs Llc | Use of toll-like receptor and agonist for treating cancer |
IN2014MN01513A (pt) * | 2012-02-07 | 2015-09-11 | Jolla Inst Allergy Immunolog | |
US20130217122A1 (en) | 2012-02-21 | 2013-08-22 | The Trustees Of The University Of Pennsylvania | Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library |
WO2013143026A1 (en) * | 2012-03-31 | 2013-10-03 | Abmart (Shanghai) Co., Ltd | Peptide and antibody libraries and uses thereof |
TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
CN103897047B (zh) * | 2012-12-27 | 2016-01-20 | 中国科学院植物研究所 | 蛋白BhHSP70-1及其编码基因与应用 |
SG11201506727RA (en) | 2013-03-01 | 2015-09-29 | Astex Pharmaceuticals Inc | Drug combinations |
CN107073090A (zh) | 2014-04-30 | 2017-08-18 | 哈佛学院董事会 | 结合的疫苗装置和杀死癌细胞的方法 |
WO2016056596A1 (ja) | 2014-10-07 | 2016-04-14 | 日本電気株式会社 | Hsp70由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法 |
US10526388B2 (en) | 2015-03-09 | 2020-01-07 | Cytlimic Inc. | Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells |
EP3281641B1 (en) | 2015-04-07 | 2020-12-16 | Cytlimic Inc. | Adjuvant for cancer vaccines |
-
2015
- 2015-10-07 WO PCT/JP2015/078504 patent/WO2016056596A1/ja active Application Filing
- 2015-10-07 US US15/516,918 patent/US10537626B2/en active Active
- 2015-10-07 BR BR112017006969A patent/BR112017006969A2/pt not_active IP Right Cessation
- 2015-10-07 RU RU2017115719A patent/RU2684911C2/ru active
- 2015-10-07 CN CN201580054234.7A patent/CN107001418A/zh active Pending
- 2015-10-07 DK DK15849707.3T patent/DK3205661T3/da active
- 2015-10-07 TW TW104133022A patent/TWI687434B/zh not_active IP Right Cessation
- 2015-10-07 AU AU2015329070A patent/AU2015329070B2/en active Active
- 2015-10-07 CA CA3116265A patent/CA3116265A1/en not_active Abandoned
- 2015-10-07 CA CA2963909A patent/CA2963909C/en active Active
- 2015-10-07 JP JP2016553137A patent/JP6423889B2/ja active Active
- 2015-10-07 ES ES15849707T patent/ES2882827T3/es active Active
- 2015-10-07 EP EP15849707.3A patent/EP3205661B1/en active Active
- 2015-10-07 EP EP21174944.5A patent/EP3925968A3/en active Pending
-
2018
- 2018-12-06 AU AU2018274976A patent/AU2018274976B2/en active Active
-
2019
- 2019-12-16 US US16/715,758 patent/US11304997B2/en active Active
-
2022
- 2022-03-11 US US17/693,046 patent/US20220193213A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2018274976B2 (en) | 2019-05-02 |
US20180169199A1 (en) | 2018-06-21 |
AU2018274976A1 (en) | 2019-01-03 |
US20200121772A1 (en) | 2020-04-23 |
AU2015329070B2 (en) | 2018-11-22 |
CA2963909C (en) | 2021-06-15 |
RU2017115719A3 (pt) | 2018-11-14 |
JP6423889B2 (ja) | 2018-11-14 |
ES2882827T3 (es) | 2021-12-02 |
RU2017115719A (ru) | 2018-11-14 |
CA3116265A1 (en) | 2016-04-14 |
EP3205661B1 (en) | 2021-07-07 |
AU2015329070A1 (en) | 2017-04-27 |
CN107001418A (zh) | 2017-08-01 |
US10537626B2 (en) | 2020-01-21 |
CA2963909A1 (en) | 2016-04-14 |
JPWO2016056596A1 (ja) | 2017-08-17 |
EP3925968A3 (en) | 2022-03-02 |
RU2684911C2 (ru) | 2019-04-16 |
WO2016056596A1 (ja) | 2016-04-14 |
TW201619190A (zh) | 2016-06-01 |
US11304997B2 (en) | 2022-04-19 |
US20220193213A1 (en) | 2022-06-23 |
TWI687434B (zh) | 2020-03-11 |
DK3205661T3 (da) | 2021-08-02 |
EP3205661A1 (en) | 2017-08-16 |
EP3925968A2 (en) | 2021-12-22 |
EP3205661A4 (en) | 2018-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120729T1 (el) | Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
BR112017018703A2 (pt) | peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno | |
TN2017000085A1 (en) | Polypeptide having a polyester degrading activity and uses thereof | |
BR112017008696A2 (pt) | métodos e composições para células exterminadoras naturais | |
BR112016016658A2 (pt) | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão | |
BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
BR112017006969A2 (pt) | peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno | |
BR112017016068A2 (pt) | composições para modulação de expressão de c9orf72 | |
ZA201506093B (en) | Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure | |
EP3936141A3 (en) | Anti-senescence compounds and uses thereof | |
ES2721309T3 (es) | Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa | |
ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
MX2016014414A (es) | Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico. | |
MX2016002937A (es) | Vacuna oncologica. | |
AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
MX371033B (es) | Productos farmacéuticos mejorados de péptido para resistencia a la insulina. | |
BR112018006006A2 (pt) | receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica | |
BR112018012304A2 (pt) | composições e métodos para diminuir expressão de tau | |
BR112017013453A2 (pt) | novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório | |
MY193807A (en) | T-cell receptor and uses thereof | |
BR112016016103A2 (pt) | Composição de antígenos micobacterianos | |
WO2015198240A3 (en) | Compositions and methods for long acting proteins | |
EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
BR112016019390A2 (pt) | proteínas de fusão uti |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15K | Others concerning applications: alteration of classification |
Ipc: C07K 7/06 (2006.01), A61K 38/00 (2006.01), A61K 39 |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2743 DE 01-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |